Literature DB >> 30552456

Hypoactivity of rat detrusor muscle in a model of cystitis: exacerbation by non-selective COX inhibitors and amelioration by a selective DP1 receptor antagonist.

Wesam Bassiouni1, Tahia Daabees1, Xavier Norel2, Amira M Senbel3,4,5.   

Abstract

Various studies have confirmed that prostaglandins (PG) alter the bladder motor activity and micturition reflex in both human and animals. However, no sufficient data is reported about the effect of cyclooxygenase (COX) inhibitors neither in normal bladder physiology nor in pathological conditions. This study aims to compare the potential effects of some COX inhibitors with varying COX-1/COX-2 selectivities (indomethacin, ketoprofen, and diclofenac) with that of the selective COX-2 inhibitor (DFU) on bladder function. The role played by some PGs and their receptors in controlling detrusor muscle function in normal condition and in cystitis is also studied. Organ bath experiments were performed using isolated rat detrusor muscle. Direct and neurogenic contractions were induced using ACh and electric stimulation (EFS), respectively. A model of hemorrhagic cystitis was induced by single injection of cyclophosphamide (300 mg/kg) in rats, and confirmed by histophathological examination. Results are expressed as mean ± SEM of 5-9 rats. Alprostadil and iloprost (1 nM- 10 µM) concentration-dependently potentiated ACh (100 μM)- and EFS (4 Hz)-induced contraction, with maximum potentiation of 40.01 ± 5.29 and 27.59 ± 6.64%, respectively, in case of ACh contractions. In contrast, ONO-AE1-259 (selective EP2 agonist, 1 nM-10 μM) inhibited muscle contraction. SC51322 (EP1-antagonist, 10 μM) and RO1138452 (IP antagonist, 10 μM) inhibited both direct and neurogenic responses. Hemorrhagic cystitis reduced both ACh and EFS responses as well as the potentiatory effect of iloprost and the inhibitory effect of RO1138452 on ACh contractions. ONO-AE3-237 (DP1 antagonist, 1 μM) significantly potentiated contractions in cystitis but showed no effect in normal bladder. A significant inhibition of contractile response was observed in presence of indomethacin, ketoprofen, and diclofenac at all tested concentrations (20, 50, and 100 μM). Highest effect was induced by diclofenac. The effect of these COX inhibitors on EFS contractions was intensified in case of cystitis, indomethacin being the most potent. Atropine (1 nM) significantly reduced indomethacin effect on ACh contraction only in normal rats. On the other hand, DFU (10-6 M) significantly potentiated the contractile effect of ACh in case of cystitis although it showed no effect in normal rats. EP1 receptors seem to play an important role in rat bladder contractility. DP1 receptors as COX-2, on the other hand, gain an important role only in case of cystitis. The use of non-selective COX inhibitors in cystitis may be associated with bladder hypoactivity; selective COX-2 inhibitors may be a safer option.

Entities:  

Keywords:  COX inhibitors; Cystitis; Detrusor muscle; Prostanoid

Mesh:

Substances:

Year:  2018        PMID: 30552456     DOI: 10.1007/s00210-018-01599-7

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  54 in total

1.  Role of prostanoid IP and EP receptors in mediating vasorelaxant responses to PGI2 analogues in rat tail artery: Evidence for Gi/o modulation via EP3 receptors.

Authors:  Nelson N Orie; Lucie H Clapp
Journal:  Eur J Pharmacol       Date:  2010-12-24       Impact factor: 4.432

Review 2.  International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes.

Authors:  R A Coleman; W L Smith; S Narumiya
Journal:  Pharmacol Rev       Date:  1994-06       Impact factor: 25.468

3.  Tachykinin antagonists and capsaicin-induced contraction of the rat isolated urinary bladder: evidence for tachykinin-mediated cotransmission.

Authors:  C A Maggi; R Patacchini; P Santicioli; S Giuliani
Journal:  Br J Pharmacol       Date:  1991-06       Impact factor: 8.739

4.  Urodynamic effects of a novel EP(1) receptor antagonist in normal rats and rats with bladder outlet obstruction.

Authors:  Tack Lee; Petter Hedlund; Donald Newgreen; Karl-Erik Andersson
Journal:  J Urol       Date:  2007-04       Impact factor: 7.450

Review 5.  The role of prostanoids in urinary bladder physiology.

Authors:  Mohammad S Rahnama'i; Philip E V van Kerrebroeck; Stefan G de Wachter; Gommert A van Koeveringe
Journal:  Nat Rev Urol       Date:  2012-03-13       Impact factor: 14.432

6.  Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes.

Authors:  Y Boie; R Stocco; N Sawyer; D M Slipetz; M D Ungrin; F Neuschäfer-Rube; G P Püschel; K M Metters; M Abramovitz
Journal:  Eur J Pharmacol       Date:  1997-12-11       Impact factor: 4.432

7.  Receptors involved in the modulation of guinea pig urinary bladder motility by prostaglandin D2.

Authors:  Na N Guan; Karl Svennersten; Petra J de Verdier; N Peter Wiklund; Lars E Gustafsson
Journal:  Br J Pharmacol       Date:  2015-06-26       Impact factor: 8.739

8.  Effect of intrathecal administration of E-series prostaglandin 1 receptor antagonist in a cyclophosphamide-induced cystitis rat model.

Authors:  Naoki Wada; Seiji Matsumoto; Masafumi Kita; Masaki Watanabe; Kazumi Hashizume; Hidehiro Kakizaki
Journal:  Int J Urol       Date:  2012-08-26       Impact factor: 3.369

9.  Inhibition of nitric oxide synthase prevents muscarinic and purinergic functional changes and development of cyclophosphamide-induced cystitis in the rat.

Authors:  Patrik Aronsson; Renata Vesela; Martin Johnsson; Yasin Tayem; Vladimir Wsol; Michael Winder; Gunnar Tobin
Journal:  Biomed Res Int       Date:  2014-06-01       Impact factor: 3.411

10.  The effect of indomethacin on the muscarinic induced contractions in the isolated normal guinea pig urinary bladder.

Authors:  Mohammad S Rahnama'i; Gommert A van Koeveringe; Philip E V van Kerrebroeck; Stefan G G de Wachter
Journal:  BMC Urol       Date:  2013-02-07       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.